Zhang Jun, Lv Jianguang, Zhang Feng, Che Hongmin, Liao Qiwei, Huang Wobin, Li Shaopeng, Li Yuqian
Department of Neurosurgery, Dalang Hospital, Dongguan, 523770, Guangdong, China.
Department of Neurosurgery, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511447, Guangdong, China.
J Neurooncol. 2017 Jul;133(3):553-559. doi: 10.1007/s11060-017-2464-2. Epub 2017 May 27.
Accumulating evidence has supported the role of microRNAs in the initiation and development of malignant tumors. MicroRNA-211 (miR-211), which was reported to involve in diverse physiological activities in several cancers, was investigated for its expression in human glioma and adjacent normal brain tissues, as well as its correlation with patient prognosis. Glioma tissues and adjacent normal brain tissues were obtained from 82 patients who underwent surgical resection, and quantitative real-time polymerase chain reaction was performed to assess the expression level of miR-211. Here, we found that miR-211 was significantly decreased in glioma tissues compared with adjacent normal brain tissues (glioma, 3.52 ± 0.14 vs. normal, 4.96 ± 0.17, p < 0.001), and inversely associated with ascending WHO classification (grade III-IV, 3.16 ± 0.21 vs. grade I-II, 4.22 ± 0.26, p < 0.001). Then, the correlation of miR-211 with clinicopathological factors was investigated by Pearson's Chi square test, indicating that miR-211 might be a potential biomarker to predict the malignant status of glioma. Further, Kaplan-Meier curves with log-rank analysis were carried out to determine the relationship between miR-211 expression level and the overall survival rate of glioma patients. Our data showed that there was a close correlation between down-regulated miR-211 and shorter survival time in 82 patients (p = 0.026). Finally, the multivariate Cox regression analysis indicated that WHO grade (HR = 2.437, 95% CI 1.251-4.966, p = 0.007), KPS (HR = 2.215, 95% CI 1.168-4.259, p = 0.016), and miR-211 expression level (HR = 3.614, 95% CI 2.152-6.748, p < 0.001) were considered as independent risk factors for glioma prognosis. These results suggested that lower miR-211 expression might be a marker for poor prognosis of glioma patients.
越来越多的证据支持了微小RNA在恶性肿瘤发生和发展中的作用。据报道，微小RNA-211（miR-211）参与多种癌症的不同生理活动，本研究对其在人脑胶质瘤组织及邻近正常脑组织中的表达情况及其与患者预后的相关性进行了研究。从82例行手术切除的患者中获取胶质瘤组织和邻近正常脑组织，并采用定量实时聚合酶链反应评估miR-211的表达水平。在此，我们发现与邻近正常脑组织相比，miR-211在胶质瘤组织中的表达显著降低（胶质瘤组，3.52±0.14 vs.正常组，4.96±0.17，p<0.001），且与世界卫生组织（WHO）分级升高呈负相关（III-IV级，3.16±0.21 vs. I-II级，4.22±0.26，p<0.001）。然后，通过Pearson卡方检验研究miR-211与临床病理因素的相关性，表明miR-211可能是预测胶质瘤恶性状态的潜在生物标志物。此外，采用Kaplan-Meier曲线结合对数秩检验来确定miR-211表达水平与胶质瘤患者总生存率之间的关系。我们的数据显示，在82例患者中，miR-211表达下调与较短的生存时间密切相关（p=0.026）。最后，多因素Cox回归分析表明，WHO分级（HR=2.437，95%CI 1.251-4.966，p=0.007）、KPS（HR=2.215，95%CI 1.168-4.259，p=0.016）和miR-211表达水平（HR=3.614，95%CI 2.152-6.748，p<0.001）被认为是胶质瘤预后的独立危险因素。这些结果表明，较低的miR-211表达可能是胶质瘤患者预后不良的一个标志物。
